ONO Pharmaceutical Co. Ltd.

12/06/2023 | Press release | Distributed by Public on 12/05/2023 23:01

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the[...]

 This material is intended to notify the press release issued on December 5 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.